![]() ![]() According to AnPac, the Nasdaq staff does not believe AnPac is eligible for a second 180-day compliance period because the firm has not demonstrated that it has shareholders ’ equity of at least $5 million. ![]() 9, the company received a letter from Nasdaq saying its stock would be delisted after failing to regain compliance with the $1 minimum bid price within the 180 - day compliance period, which ended on Sept. Until the hearing, and pending a final written decision by the panel, AnPac Bio’s stock will continue to be traded on the Nasdaq. 20, to appeal the firm’s delisting from the stock exchange. ![]() The results were in line with the company’s previously announced preliminary results.ĪnPac Bio said this week that the Nasdaq Hearings Panel has granted it a hearing, scheduled for Oct. Its cash position was €6.0 million at the end of the first half of 2022. The firm’s net loss totaled €56,000 compared to €92,000 in the prior-year period. Total revenues rose 15 percent to €6.3 million ($6.3 million) from €5.5 million in the same period last year. The announcement builds on a collaboration with Illumina launched in January 2021.įrench diagnostic s company Theradiag announced its earnings results for the first half of 2022 this week. Helix, with resources from the Broad Institute and the University of Washington School of Medicine, will conduct genomic sequencing of SARS-CoV-2 to provide baseline information for the CDC's national and state-level viral monitoring efforts. Helix said this week that it has extended its SARS-CoV-2 sequencing and surveillance collaboration with the US Centers for Disease Control and Prevention. Financial and other terms of the deal were also undisclosed. Under the deal, the distributor will sell T2 Biosystems’ T2Dx instruments and the T2 Bacteria, T2Candida, and T2Resistance panels. T2 Biosystems said this week it has signed an exclusive distribution agreement with an unnamed company covering the Baltic region including Lithuania, Latvia, and Estonia. 23 and replaces Hologic's previous $1 billion share repurchase authorization, which had about $150 million remaining. The program took effect at the close of trading on Sept. Hologic said this week its board of directors have authorized a new $1 billion stock repurchase program with a five-year term. The recipients are the Access Community Health Center in Madison, Wisconsin AtlantiCare Health Services in Atlantic City, New Jersey Community HealthCare Network in New York Angeles Community Health Center in Los Angeles Mari p o sa Community Health Center in Santa Cruz County, Arizona Mount Sinai Internal Medicine Associates in New York Mountain Park Health Center in Phoenix, Arizona and San Joaquin Health Center in Stockton, California. Under the program, called Funding Opportunities for CRC Screening Uptake Strategies (FOCUS), awardees will implement intervention strategies to increase colorectal cancer screening rates. Through its sponsorship, Thermo Fisher said it will provide its “ advanced technology and expertise to emerging biotech residents.”Įxact Sciences said this week that it has awarded $525,000 in grants to eight health centers that focus on improving colorectal cancer screening rates in vulnerable populations. A nonprofit life sciences incubator-accelerator, the PABC has an existing campus in Doylestown, Pennsylvania, and a new B+Labs incubator in Philadelphia in partnership with the Brandywine Realty Trust. Separately, the firm said this week that it has become a founding sponsor for the Pennsylvania Biotechnology Center (PABC). Thermo Fisher said the new site is part of its $650 million multi-year investment to expand its bioprocessing production capabilities. The facility, which cost $160 million and spans 85,000 square feet, will support purification process es for the development of biotherapeutics and vaccines. NEW YORK – Thermo Fisher Scientific said this week that it has opened a new biomanufacturing facility in Chelmsford, Massachusetts. Advances in Clinical Genomics Profiling. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |